⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Xiu-Zhi Zhu Hu-Yun-Long Zhang Yi-Fan Zhou Yi-Yu Chen Tong Fu Ming-Liang Jin Ya-Xin Zhao Yi-Fan Xie Xiaohua Zeng Xi Jin Yi‐Zhou Jiang Zhi‐Ming Shao

View at Publisher

Ask AI

Bookmark

Share

Key Points

Precision treatment improves therapy for HR+/HER2− breast cancer, leading to better patient outcomes.
Mean IC50 values for tyrosine kinase inhibitors were assessed across various SNF subtypes, highlighting effectiveness differences.
Analysis of SNF subtypes offers a tailored approach to treatment over the traditional one-size-fits-all strategy.
This approach underlines the importance of individualized therapy in breast cancer to enhance treatment efficacy.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals improved efficacy of precision treatment in patients with HR+ and HER2− breast cancer, indicating better outcomes with subtyping.

Abstract

Mean IC50 of tyrosine kinase inhibitors in SNF subtypes

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcaa5 https://doi.org/10.1158/0008-5472.30363448

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
2Table S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
3Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
4Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
5Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025

Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025